DnB Asset Management AS Buys 22,590 Shares of Kenvue Inc. (NYSE:KVUE)

DnB Asset Management AS boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 381,232 shares of the company’s stock after acquiring an additional 22,590 shares during the period. DnB Asset Management AS’s holdings in Kenvue were worth $8,139,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Townsquare Capital LLC increased its position in shares of Kenvue by 25.3% during the third quarter. Townsquare Capital LLC now owns 52,713 shares of the company’s stock valued at $1,219,000 after purchasing an additional 10,629 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Kenvue by 30.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 9,992,933 shares of the company’s stock valued at $231,137,000 after buying an additional 2,316,443 shares during the period. White Knight Strategic Wealth Advisors LLC bought a new stake in Kenvue in the 3rd quarter valued at $256,000. Alerus Financial NA raised its stake in shares of Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after buying an additional 491 shares in the last quarter. Finally, Paloma Partners Management Co bought a new position in shares of Kenvue during the 3rd quarter worth about $360,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on KVUE. Barclays increased their price target on shares of Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Thursday. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price target on the stock. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Finally, Canaccord Genuity Group upped their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $24.00.

Kenvue Stock Up 1.0 %

NYSE KVUE opened at $23.74 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The stock has a market capitalization of $45.36 billion, a P/E ratio of 44.78, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The stock has a fifty day moving average of $22.32 and a 200-day moving average of $22.45.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.45%. Kenvue’s payout ratio is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.